The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer

Abstract

BackgroundThe role of tumor protein D54 in breast cancer has not been studied and its function in breast cancer remains unclear. In our previous pharmacogenomic studies using lymphoblastoid cell line (LCL), this protein has been identified to affect metformin response. Although metformin has been widely studied as a prophylactic and chemotherapeutic drug, there is still a lack of biomarkers predicting the response to metformin in breast cancer. In this study, we revealed the novel function of TPD54 in breast cancer through understanding how TPD54 altered the cancer cell sensitivity to metformin.MethodsThe role of TPD54 in altering cellular sensitivity to metformin treatment was carried out by either knockdown or overexpression of TPD54, followed by measuring cell viability and reactive oxygen species (ROS) production in MCF7 breast cancer cell line and breast cancer patient-derived xenografts. Functional analysis of TPD54 in breast cancer cells was demonstrated by studying TPD54 protein localization and identification of potential binding partners of TPD54 through immunoprecipitation followed by mass spectrometry. The effect of TPD54 on pyruvate dehydrogenase (PDH) protein regulation was demonstrated by western blot, immunoprecipitation, and site-directed mutagenesis.ResultsTPD54 inhibited colony formation and enhanced cellular sensitivity to metformin treatment in MCF7 cells and breast cancer patient-derived xenografts. Mechanistic study indicated that TPD54 had mitochondrial localization, bound to and stabilized pyruvate dehydrogenase E1α by blocking pyruvate dehydrogenase kinase 1 (PDK1)-mediated serine 232 phosphorylation. TPD54 knockdown increased PDH E1α protein degradation and led to decreased PDH enzyme activity, which reduced mitochondrial oxygen consumption and reactive oxygen species (ROS) production, thus contributing to the resistance of breast cancer cells to metformin treatment.ConclusionWe have discovered a novel mechanism by which TPD54 regulates pyruvate dehydrogenase and affects the sensitivity of breast cancer to metformin treatment. Our findings highlight the important post-translational regulation of PDK1 on PDH E1α and the potential application of TPD54 as a biomarker for selecting tumors that may be sensitive to metformin therapy. These provide new insights into understanding the regulation of PDH complexes and the resistance mechanisms of cancer cells to metformin treatment.Electronic supplementary materialThe online version of this article (10.1186/s40170-018-0193-4) contains supplementary material, which is available to authorized users.

NMR-Based Metabolomics Approach to Investigate the Effects of Fruits of Acanthopanax sessiliflorus in a High-Fat Diet Induced Mouse Model

“…In this experiment, the level of formate was decreased in the high-fat diet. These results were the same as those of previous studies, which also showed that the formate level was significantly decreased in the obese group compared to the healthy control group [ 32 ]. Inosine, an endogenous metabolic derivative of adenosine, decreased in the high-fat diet group and increased in the positive control group and the A. sessiliflorus fruit administration group.…”

Beneficial Effects of Bariatric Surgery-Induced by Weight Loss on the Proteome of Abdominal Subcutaneous Adipose Tissue

“…Tumor protein D54 (TPD54) is another protein that we found to be greatly increased after weight loss. Recently its mitochondrial location has been demonstrated, and it has been hypothesized that TPD54 knockdown decreases pyruvate dehydrogenase enzyme activity, reducing mitochondrial oxidative phosphorylation [64].…”

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors

“…Due to their mechanism of action—improvement in hyperglycemia, insulin sensitivity, decreased body weight—there were also expectations for their beneficial effect on cancer risk. In vitro and animal studies show their significant potential for protection against cancer formation and progression [ 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 ]. However, randomized and observational studies, and their meta-analyzes, did not confirm these hopes [ 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 ].…”

“…This effect was abrogated by insulin infusion. Thus, in case of obesity-related cancers canagliflosin exerts its oncoprotective effect through insulin- and glucose-lowering action [ 134 ]. In a study by Shiba et al canagliflozin attenuated development of HCC in a mouse model of human NASH.…”